XORTX Therapeutics Inc. (XRTX.V)
CAD 1.2
(-10.45%)
CAD 1.2
(-10.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 6.38 Million CAD | -35.29% |
| 2022 | 9.86 Million CAD | 244.55% |
| 2021 | 2.86 Million CAD | 120.09% |
| 2020 | 1.3 Million CAD | 129.79% |
| 2019 | 565.96 Thousand CAD | -51.09% |
| 2018 | 1.15 Million CAD | 149.37% |
| 2017 | 464.06 Thousand CAD | 14.49% |
| 2016 | 405.33 Thousand CAD | 0.0% |
| 2014 | 36.92 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.08 Million USD | 10.67% |
| 2024 Q2 | 1.49 Million USD | 37.21% |
| 2023 Q2 | 1.76 Million USD | -7.63% |
| 2023 FY | 7.97 Million CAD | -19.17% |
| 2023 Q3 | 1.39 Million USD | -20.91% |
| 2023 Q4 | 983.67 Thousand USD | -29.4% |
| 2023 Q1 | 1.9 Million USD | -47.22% |
| 2022 Q2 | 3.38 Million CAD | -7.05% |
| 2022 Q1 | 3.64 Million CAD | 126.35% |
| 2022 Q4 | 3.61 Million CAD | 31.66% |
| 2022 Q3 | 2.74 Million CAD | -18.9% |
| 2022 FY | 9.86 Million CAD | 244.55% |
| 2021 FY | 2.86 Million CAD | 120.09% |
| 2021 Q4 | 1.6 Million CAD | 297.34% |
| 2021 Q2 | 865.44 Thousand CAD | 12.33% |
| 2021 Q1 | 770.45 Thousand CAD | 102.57% |
| 2021 Q3 | 404.87 Thousand CAD | -53.22% |
| 2020 Q4 | 380.34 Thousand CAD | -0.39% |
| 2020 Q2 | 370.89 Thousand CAD | 121.53% |
| 2020 Q1 | 167.42 Thousand CAD | 1.54% |
| 2020 FY | 1.3 Million CAD | 129.79% |
| 2020 Q3 | 381.84 Thousand CAD | 2.95% |
| 2019 Q1 | 127.65 Thousand CAD | 105.16% |
| 2019 FY | 565.96 Thousand CAD | -51.09% |
| 2019 Q2 | 140.25 Thousand CAD | 9.87% |
| 2019 Q4 | 164.88 Thousand CAD | 23.81% |
| 2019 Q3 | 133.17 Thousand CAD | -5.04% |
| 2018 Q1 | 3.05 Million CAD | 1169.88% |
| 2018 Q4 | -2.47 Million CAD | -940.78% |
| 2018 Q2 | 276.98 Thousand CAD | -90.94% |
| 2018 Q3 | 293.97 Thousand CAD | 6.13% |
| 2018 FY | 1.15 Million CAD | 149.37% |
| 2017 Q1 | 67.15 Thousand CAD | 16.84% |
| 2017 FY | 464.06 Thousand CAD | 14.49% |
| 2017 Q4 | 240.8 Thousand CAD | 167.99% |
| 2017 Q3 | 89.85 Thousand CAD | 89.25% |
| 2017 Q2 | 47.48 Thousand CAD | -29.3% |
| 2016 FY | 405.33 Thousand CAD | 0.0% |
| 2016 Q4 | 57.47 Thousand CAD | 10.37% |
| 2016 Q3 | 52.07 Thousand CAD | 17.8% |
| 2016 Q2 | 44.2 Thousand CAD | 425.13% |
| 2016 Q1 | -13.59 Thousand CAD | -112.47% |
| 2015 Q1 | 17.39 Thousand CAD | 171.9% |
| 2015 Q2 | 62.62 Thousand CAD | 259.93% |
| 2015 Q4 | 109.05 Thousand CAD | 134.24% |
| 2015 Q3 | 46.55 Thousand CAD | -25.66% |
| 2014 Q3 | 6678.00 CAD | 3.6% |
| 2014 FY | 36.92 Thousand CAD | 0.0% |
| 2014 Q2 | 6446.00 CAD | 0.0% |
| 2014 Q4 | 6399.00 CAD | -4.18% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Biopartners Inc. | 3.22 Million CAD | -97.816% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 55.564% |
| Hemostemix Inc. | 2.15 Million CAD | -195.903% |
| Universal Ibogaine Inc. | 5.81 Million CAD | -9.71% |
| Kane Biotech Inc. | 3.46 Million CAD | -84.082% |
| MedMira Inc. | 1.5 Million CAD | -322.807% |
| Marvel Biosciences Corp. | 2.31 Million CAD | -175.207% |
| NervGen Pharma Corp. | 17.77 Million CAD | 64.1% |